key: cord-0803243-ydrv407s
authors: Ke, Calvin; Narayan, K. M. Venkat; Chan, Juliana C. N.; Jha, Prabhat; Shah, Baiju R.
title: Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
date: 2022-05-04
journal: Nat Rev Endocrinol
DOI: 10.1038/s41574-022-00669-4
sha: b3c8f01267c07ad855b3b882f14f51a825820310
doc_id: 803243
cord_uid: ydrv407s

Nearly half of all adults with type 2 diabetes mellitus (T2DM) live in India and China. These populations have an underlying predisposition to deficient insulin secretion, which has a key role in the pathogenesis of T2DM. Indian and Chinese people might be more susceptible to hepatic or skeletal muscle insulin resistance, respectively, than other populations, resulting in specific forms of insulin deficiency. Cluster-based phenotypic analyses demonstrate a higher frequency of severe insulin-deficient diabetes mellitus and younger ages at diagnosis, lower β-cell function, lower insulin resistance and lower BMI among Indian and Chinese people compared with European people. Individuals diagnosed earliest in life have the most aggressive course of disease and the highest risk of complications. These characteristics might contribute to distinctive responses to glucose-lowering medications. Incretin-based agents are particularly effective for lowering glucose levels in these populations; they enhance incretin-augmented insulin secretion and suppress glucagon secretion. Sodium–glucose cotransporter 2 inhibitors might also lower blood levels of glucose especially effectively among Asian people, while α-glucosidase inhibitors are better tolerated in east Asian populations versus other populations. Further research is needed to better characterize and address the pathophysiology and phenotypes of T2DM in Indian and Chinese populations, and to further develop individualized treatment strategies.

Type 2 diabetes mellitus (T2DM) is a complex, heritable and heterogeneous condition that manifests in a range of phenotypes 1 . Characterizing these phenotypes could reveal insights into the underlying pathophysiology, which is relevant in individualizing clinical management to each patient 2,3 . There is keen interest in personalizing the treatment of T2DM using a 'precision medicine' approach that integrates epidemiological, phenotypic, genetic and molecular data 4, 5 . However, much of the evidence in this arena has been limited to studies in populations of European descent.

Of the estimated 463 million adults with diabetes mellitus globally, >90% have T2DM and nearly half live in two large countries: India and the People's Republic of China (henceforth referred to as China) 6 . Indian and Chinese people exhibit differences in the characteristics of T2DM compared with people of European descent, including a younger age at diagnosis, greater tendency towards β-cell failure and leaner body habitus [7] [8] [9] . In these populations, novel analytical approaches have revealed phenotypic variations in young-onset T2DM (defined in this Review as age at diagnosis <40 years 10 ) and other subtypes of T2DM, and have revealed unique responses to certain glucose-lowering medications (for example, sodium-glucose cotransporter 2 (SGLT2) inhibitors and α-glucosidase inhibitors). Examining how the pathophysiology and phenotypes of T2DM vary among Indian and Chinese people could generate valuable insights to inform the development, refinement and broader implementation of precision medicine strategies.

In this Review, we synthesize the latest evidence regarding the epidemiology, pathophysiology, phenotypes and glycaemic management of T2DM among Indian and Chinese populations and their diasporas, and identify novel avenues of research to advance therapeutic approaches. Because the vast majority (98.0-99.7% 11, 12 ) of Chinese and Indian adults with diabetes mellitus have T2DM, we included population-based studies of 10 15.20-20.90 8.18-8. 58 13.50-15.20 6. 80-8.18 12.30-13.50 6.22-6. 80 10.70-12.30 5.30-6. 22 6. 30-10.70 Crude prevalence of diabetes mellitus (%) Crude prevalence rates are shown to illustrate spatial distribution. Rates are not directly comparable between countries owing to differences in the age distribution between countries (comparable age-standardized data unavailable). In China and India, the rising prevalence of diabetes mellitus is driven by rapid urbanization, increased caloric intake and reduced physical activity [255] [256] [257] [258] . The high crude prevalence and number of people with diabetes mellitus in China relative to India is driven in part by China's older age distribution 259, 260 . Panel a is derived from data from the International Diabetes Federation Atlas 6 . Panel b is derived from data from the United Nations, Department of Economic and Social Affairs, & Population Division 261 . Panel c is derived from data from the Food and Agriculture Organization of the United Nations 253, 254 . Panel d is derived from data from Tandon et al. 262 and Li et al. 53 .

Pathophysiology Insulin resistance and impairments in insulin secretion are crucial factors in the pathophysiology of T2DM 26, 27 (Box 2). Insulin is secreted by pancreatic β-cells in response to rising arterial concentrations of glucose 28 . First-phase insulin release peaks at 2-4 min after the initial rise in arterial levels of glucose and drops sharply by 10-15 min, while second-phase insulin release is more gradual, achieving a steady state at 2-3 h after the initial rise in arterial levels of glucose 28 . Under conditions of insulin resistance, β-cells are stimulated to secrete more insulin than under conditions of normal insulin sensitivity 28 . Insufficient insulin secretion, especially in the presence of insulin resistance, glucolipotoxicity and obesity-related inflammation, results in hyperglycaemia and, eventually, T2DM 29 .

Although the natural history of T2DM has been traditionally described as a process of increasing age-related insulin resistance followed by declining β-cell function and insufficient insulin secretion, it has been postulated that people predisposed to T2DM probably have a primary genetic factor that impairs β-cell function 26, 28, 30 . This hypothesis is based partly on studies that demonstrate reduced first-phase and second-phase insulin secretion among healthy, normoglycaemic and insulin-sensitive first-degree relatives of people with T2DM 28 . Accordingly, T2DM might develop among genetically predisposed people when obesity or other factors such as age increase insulin resistance to overwhelm their intrinsically limited β-cell insulin secretion. Several studies in south Asian populations suggested that people of Indian origin develop early β-cell failure in response to increased insulin resistance. This concept was demonstrated in the prospective British Whitehall study of 5,749 white civil servants and 230 civil servants of south Asian origin without diabetes mellitus at baseline (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) 31 . In this cohort, the Homeostatic Model Assessment of insulin sensitivity (HOMA-S) was lower among people of south Asian origin than in white people, but declined with age in both groups. However, the increase in the Homeostatic Model Assessment of β-cell function (HOMA-β), which might reflect a compensatory response to insulin resistance, was much greater and peaked around 15 years earlier (at age 50-60 years) in people of south Asian origin than in white people. During the study, fasting blood levels of glucose remained constant among white people but increased linearly with time among people of south Asian origin, indicating that compensatory insulin secretion was insufficient to overcome insulin resistance. These differences were partially explained by higher rates of obesity, less healthy dietary patterns and lower socioeconomic status in the south Asian versus the white population. Similar findings were reported in the Netherlands 32 and in the Mediators of Atherosclerosis in South Asians Living in America (MASALA) and the Multiethnic Study of Atherosclerosis (MESA) cohorts of US adults with or without diabetes mellitus 33 .

By contrast, many people of Chinese origin seem to exhibit progressive β-cell failure despite declining insulin resistance over time. In the MASALA and MESA cohorts, HOMA-β dropped sharply during adulthood up to age 60 years, followed by a steadier decline after this age, in the presence of steadily declining Homeostatic Model Assessment of insulin resistance (HOMA-IR) across all ages 33 . In a systematic review, east Asian people (defined here as having an ethnic origin from China, Japan, South Korea or Taiwan) had high sensitivity to insulin but a severely limited innate capacity to secrete insulin 34 . This limited capacity meant that even a small reduction in insulin secretion (for example, due to ageing or β-cell exhaustion) would result in T2DM.

In the MASALA and MESA cohorts 33 , HOMA-β was statistically significantly lower in south Asian people than in Chinese people 33 . Insulin secretion among south Asian and Chinese people was the lowest among all ethnic groups. South Asian people had a higher HOMA-IR than white or Chinese people, especially at the ages of 40-60 years 33 . After age 60 years, white people had the highest insulin resistance among these ethnic groups. In the CARRS cohort of adults in India and Pakistan without diabetes mellitus at baseline, HOMA-β was statistically significantly lower in these south Asian people compared with Pima Indian people 35 and Black, but not white, people in the USA 36 after adjusting for age and BMI. In the Singapore Adults 35 . In the MASALA study, insulin secretion, measured using the oral disposition index (Box 2), was associated with progression to pre-diabetes or T2DM after a mean of 2.5 years, while the insulin sensitivity index did not significantly predict incident pre-diabetes or T2DM after accounting for the level of visceral adipose tissue 38 . In Chennai, the Diabetes Community Lifestyle Improvement programme reported that the contribution of impaired β-cell function to impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) was greater than that of insulin resistance, suggesting that β-cell dysfunction was the main contributor to IFG and IGT 39 . Studies in Chinese populations report mixed findings on the relative contributions of impaired insulin secretion and insulin resistance to T2DM pathogenesis. In Shanghai, cross-sectional studies reported worse β-cell function in people with T2DM compared with individuals with pre-diabetes, whereas insulin sensitivity was similar across groups 40, 41 . Studies in Nanjing city 42 and Zhejiang province 43 found that both β-cell function and insulin resistance were worse among people with T2DM compared with people with pre-diabetes or normal glucose tolerance. Furthermore, in Zhejiang, insulin resistance was associated with increased odds ratio of pre-diabetes, whereas impaired β-cell function was associated with increased odds ratio of T2DM 43 . The nationwide China Cardiometabolic Disease and Cancer Cohort Study of 94,952 people found that a greater proportion of incident diabetes mellitus cases were attributable to HOMA-IR (24.4%, 95% CI 23.6-25.2%) than to HOMA-β (12.4%, 95% CI 11.2-13.7%) 44 and that small increases in body weight were associated with increased risks of diabetes mellitus 44 . Although these studies seem to be conflicting, their interpretation is limited by potential confounders, including socioeconomic and health-related behavioural changes over time and the lack of dynamic insulin secretion indices.

An indirect approach to characterizing the development of T2DM involves examining epidemiological patterns of IFG and IGT, which are different states of pre-diabetes associated with distinct metabolic abnormalities and a high risk of progression to T2DM [45] [46] [47] (Fig. 2 ). In India, there is a preponderance of isolated IFG relative to isolated IGT (prevalence rate of 6.5%, 95% CI 6.3-6.7% and 2.8%, 95% CI 2.7-3.0%, respectively, in most states) 48 . This pattern is similar to white, Black and Hispanic populations in the USA, in which IFG is more common than IGT 49 . IFG is characterized by hepatic insulin resistance causing increased hepatic gluconeogenesis and reduced first-phase insulin secretion 38, 46, 50 . These changes are consistent with the observation of elevated HOMA-IR, a key indicator of hepatic insulin resistance, among people with IFG versus those with normoglycaemia 46 . Increased hepatic lipid accumulation might have an especially important role in Indian people 51 . In a multi-ethnic study of lean, healthy men in the USA, increased insulin resistance among people of Indian origin (relative to people who are not Asian and people of east Asian origin) was associated with increased hepatic tri glyceride content, suggesting a predisposition to hepatic steatosis and hepatic insulin resistance 52 .

The gold standard for quantifying insulin secretion and insulin resistance are the hyperglycaemic and euglycaemic-hyperinsulinaemic clamps, respectively 287 . During these tests, the concentration of glucose in the blood is 'clamped' at a constant concentration to reduce the confounding effects of prevailing blood levels of glucose on insulin action or secretion 287 . However, clamps are intensive and impractical to implement in large studies. Simpler surrogate measures have been developed using fasting blood tests that assess fasting levels of insulin and glucose in a steady state. The Homeostatic Model Assessment (HOMA) method is a mathematical model that indirectly estimates β-cell function (HOMAβ) or hepatic and peripheral insulin resistance (HOMA-IR) on the basis of fasting plasma levels of glucose and insulin or C-peptide concentrations 288 . There are various versions of the HOMA model 288 . The HOMA method can also quantify insulin sensitivity (HOMA-S), which is the reciprocal of HOMA-IR 288 . HOMAβ is modestly correlated with the gold standard (r = 0.69), whereas HOMA-IR is more strongly correlated with the gold standard (r = 0.88) 288, 289 . It is important to note that HOMA and clamps reflect steady and dynamic states, respectively, and could therefore be viewed as complementary measures 288 . Other methods of measuring in vivo insulin secretion have been derived using stimulated measurements with intravenous glucose, oral glucose and mixed-meal tolerance tests. These methods are reviewed elsewhere 289, 290 . In particular, the oral disposition index is a measure of insulin secretion corrected for insulin sensitivity, and this test generally yields similar results to the clamp studies 289 .

In large epidemiological studies, the decline in β-cell function over time might be indirectly quantified as glycaemic deterioration 121, 122, 291, 292 . The rate of glycaemic deterioration is equivalent to the slope of HbA 1c over time, after accounting for glucoselowering drugs using statistical adjustment 121 . As with HOMA methods 288 , glycaemic deterioration cannot be estimated among people treated with exogenous insulin 121 .

By contrast, China has a much higher prevalence of isolated IGT (11.5%, 95% CI 10.5-12.7) than isolated IFG (2.4%, 95% CI 2.0-2.9) 53 . IGT is characterized by skeletal muscle insulin resistance and changes in both first-phase and second-phase insulin secretion 46,50,54 , a finding that has been specifically confirmed in Chinese people 55 . Hyperinsulinaemic-euglycaemic clamp studies have demonstrated that insulin-stimulated glucose disposal, a key indicator of muscle insulin sensitivity, is reduced in IGT across ethnicities 46 . Furthermore, IGT could be associated with an increased risk of cardiometabolic disease compared with IFG among Chinese people 56, 57 and other populations 54 . IFG and IGT might arise from distinct β-cell abnormalities 50 and confer different risks of progression to T2DM 54 . These issues require further characterization in Chinese and Indian populations.

Genetic architecture. Genome-wide association studies (GWAS) have revealed insights into the pathophysiological mechanisms of T2DM, which is a complex polygenic disease. Most of the >500 currently identified genetic loci for T2DM [58] [59] [60] are related to β-cell function or mass 61 . Most common genetic variants are similar across populations of south Asian, east Asian and European ancestry, suggesting that genetic susceptibility to T2DM is mostly shared across ethnicities [62] [63] [64] [65] . However, some alleles vary in frequency across populations, and ancestry-specific genetic variants might partly explain some features of T2DM among Indian and Chinese populations. A south Asian GWAS that involved 5,700 Indian participants identified six novel genetic loci, including HNF4A (linked to defective insulin secretion in maturity-onset diabetes of the young type 1), GRB14 (which encodes a protein that binds to the insulin receptor and inhibits signalling) and ST6GAL1 (which encodes a protein that might influence insulin action) 64 . Other novel loci include SGCG (which encodes a protein expressed in skeletal muscle) among Indian Punjabi Sikh people 66 and TMEM163 (which encodes a synaptic vesicle membrane protein linked to insulin secretion) among Indian people 65 . In the UK Biobank, people of south Asian origin had a lower frequency of genetic variants predisposing to subcutaneous adiposity compared with the white population, which might predispose them to increased visceral adiposity and adipocyte hypertrophy, resulting in β-cell glucolipotoxicity 67 . Because the population of India is particularly genetically complex owing to endogamy and diverse sociolinguistic groupings 68 , large sample sizes are required to ensure adequately powered GWAS and to stratify by Indian subpopulation 69 .

The unique genetic variants for T2DM in Indian populations seem to be distinct from those in Chinese populations. Large GWAS have confirmed that genetic loci such as PAX4 (which encodes a pancreatic islet transcription factor), PSMD6 and ZFAND3 (which encode proteins involved in insulin secretion), NID2 (associated with lipodystrophy traits or body adipose tissue distribution after adjustment for BMI) and ALDH2 (which encodes an enzyme for alcohol metabolism associated with T2DM in men) are unusually frequent among east Asian people 60, 63, 70 , who might have limited β-cell regenerative capacity 71 . In particular, polymorphisms of PSMD6 and PAX4 (which appears to be monomorphic in people who are not east Asian 60 ) might reduce insulin secretion and β-cell functional mass, respectively 72 . These polymorphisms might also predict responses to rosiglitazone in Chinese populations (rosiglitazone is no longer used in most regions over concerns about increased cardiovascular risk 73 ) 74, 75 . Other studies suggest that genetic variants might predict responses to metformin and time to insulin therapy 76 , but further pharmacogenetic studies are required 77 .

According to the developmental origins of health and disease 'thrifty phenotype' hypothesis, intrauterine and early life exposure to malnutrition followed by an energy-rich setting in later life results in a high risk of T2DM 78 (Fig. 3) . Major events such as the great Bengal famine (1943) 79 and Chinese famine (1959) (1960) (1961) 80 affected millions of Indian and Chinese people, respectively. Fetal and childhood exposure to the Chinese famine, followed by high socioeconomic status during adulthood, were associated with increased T2DM incidence in several studies 80, 81 . The effect of famine and malnutrition might be mediated by epigenetic changes 82, 83 , decreased pancreatic β-cell proliferation and increased insulin resistance compared with individuals not exposed to famine or malnutrition 84 This conceptualization is based on the epidemiological patterns of impaired fasting glucose (IFG) versus impaired glucose tolerance (IGT) prevalence observed in India and China, the known pancreatic β-cell defects associated with IFG and IGT and evidence from single-ethnic and multi-ethnic studies. In Indian populations, β-cell dysfunction often causes reduced first-phase insulin secretion. In the presence of increased insulin resistance, especially hepatic insulin resistance, Indian people have an increased risk of developing IFG, which might ultimately lead to type 2 diabetes mellitus (T2DM). In Chinese populations, β-cell dysfunction might predispose to globally impaired insulin secretion (reduced first-phase and second-phase insulin secretion). In the presence of insulin resistance, especially skeletal muscle insulin resistance, Chinese people have an increased risk of developing IGT, which might lead to T2DM. Hepatic insulin resistance and adiposity can be more severe in Indian people than in Chinese people, thus exacerbating insulin deficiency and causing relatively early (before age 40 years) and increased incidence of T2DM. Given the heterogeneous nature of T2DM pathogenesis, these features sometimes intersect within or vary between Indian and Chinese individuals.

The practice of marrying within one's own social group.

A rare group of disorders characterized by partial or generalized loss of adipose tissue.

www.nature.com/nrendo 0123456789();: deficiency predicted low birthweight, childhood adiposity and childhood insulin resistance 85 . However, paternal T2DM is also associated with low birthweight 86 . This observation suggests that a genetic predisposition to insulin deficiency also partly explains the relationship between low birthweight and T2DM risk (the fetal insulin hypothesis) 87 . Conversely, maternal hyperglycaemia and obesity are associated with higher birthweight and increased risk of T2DM 82 compared with mothers without hyperglycaemia or obesity during pregnancy. This association was demonstrated in the prospective Mysore Parthenon Birth Cohort Study, which reported increased childhood adiposity and insulin resistance among offspring of mothers with T2DM compared with those from mothers without T2DM 88 .

Islet amyloid. Amyloid deposits within the pancreatic islets might have a role in T2DM pathogenesis by accelerating β-cell apoptosis 26, 89, 90 . An estimated 40-100% of individuals with T2DM have islet amyloid deposits 90 . A Chinese autopsy study demonstrated that individuals with T2DM were statistically significantly more likely to have islet amyloid deposits at autopsy than individuals without T2DM 91 . High dietary fat intake (which appears to be particularly common in India and China 92 ) might increase islet secretion of amyloid 89, 90 . Genetic studies investigating a link between T2DM risk and mutations of the islet amyloid polypeptide (also known as amylin) gene have shown that the S20G mutation is associated with T2DM and an earlier age at T2DM diagnosis (age <40 years) among Chinese 93 and other east Asian populations 90 , but not in Europeanorigin and Indian populations 90, 94 . Animal studies suggest that this mutation might reduce the number and function of β-cells 95 .

Gut microbiome. Emerging evidence suggests that gut microbial composition might affect T2DM risk by modulating inflammation and affecting gut permeability, insulin resistance, carbohydrate processing and fatty acid oxidation 96 . Local differences in diet and environment probably contribute to unique gut microbial signatures among Indian 97 and Chinese 98 populations. These differences could affect T2DM risk and responses to glucose-lowering drugs 97, 98 .

Infection. Infections increase insulin resistance by activating inflammatory mediators (for example, tumour necrosis factor-α (TNFα) and C-reactive protein) and could have a role in T2DM pathogenesis 99, 100 . Hepatitis B infection is common in India and China, but, unlike hepa titis C infection, has not been consistently associated with T2DM in these populations 101, 102 . Coronavirus disease 2019 (COVID-19) infection increases insulin resistance among previously normoglycaemic individuals and might predispose to future T2DM development 103 . Limited evidence suggests that tuberculosis and its treatments might increase the risk of T2DM 104, 105 .

Helicobacter pylori infection has been inconsistently linked to T2DM in Chinese populations 106, 107 .

In the Swedish All New Diabetics in Scania (ANDIS) cohort 108 , all incident cases of diabetes mellitus were classified into five subgroups using a cluster analysis based on specific phenotypic characteristics: age at diag nosis, BMI, glutamic acid decarboxylase (GAD) anti bodies, HOMA-β and HOMA-IR. The severe autoimmune diabetes mellitus subgroup consisted of people with type 1 diabetes mellitus (T1DM) and latent autoimmune diabetes mellitus of adulthood, and T2DM was divided into subgroups hypothesized to relate to disease aetiology: severe insulin-deficient diabetes mellitus, severe insulin-resistant diabetes mellitus, mild obesity-related diabetes mellitus and mild age-related diabetes mellitus 108 .

Although this method of classification has been criticized as oversimplified 109 , comparing the clinical characteristics across subgroups and populations suggests distinct phenotypes of diabetes mellitus in Indian and Chinese people (TABle 1) . In India, a cluster-based analysis was performed among people with diabetes mellitus (disease duration <5 years) identified within private clinics across nine states 110 . Although GAD antibodies were unavailable to identify severe autoimmune diabetes mellitus, when compared with the ANDIS cohort, severe insulin-deficient diabetes mellitus occurred more often (26.2% versus 17.5%), at a younger age (mean 42.5 years versus 56.7 years), at a lower BMI (mean 24.9 kg/m 2 versus 28.9 kg/m 2 ) and with lower levels of β-cell function and insulin resistance within this Indian cohort. Individuals within the remaining subgroups were also younger at diagnosis, with lower BMI and lower β-cell function compared with the ANDIS cohort. In particular, the Indian subgroup with severe insulin resistance also had low β-cell function, a characteristic not observed in the Swedish subgroup with According to the developmental origins of health and disease hypothesis, fetal or early life exposure to undernutrition results in low birthweight and adaptive responses characterized by reduced β-cell secretion and increased insulin resistance. Genetic predisposition to type 2 diabetes mellitus (T2DM) probably also contributes to these changes, as proposed by the fetal insulin hypothesis. In the context of the rapid pace of urbanization in India and China, the postnatal environment often provides excess nutrition, which further exacerbates the risk of T2DM. Health-related behaviours such as low levels of physical activity, high caloric intake, poor sleep and smoking independently raise the risk of T2DM [255] [256] [257] [258] . Some genetic variants that predispose to T2DM seem to be unique among populations of east and south Asian ancestry. However, currently identified genetic variants explain <10% of the estimated 30-70% heritability of T2DM [263] [264] [265] . This figure is not exhaustive; concepts have been simplified here for the purposes of illustration.

A type of diabetes mellitus that presents in adulthood with immunogenetic markers of type 1 diabetes mellitus, but that does not require insulin at the time of diagnosis.

Nature reviews | Endocrinology 110 .

In China, cluster-based analyses similarly revealed low levels of HOMA-β, HOMA-IR and BMI across subgroups, with younger ages at diagnosis and an increased frequency of severe insulin-deficient diabetes mellitus in some [111] [112] [113] , but not all 114 , cohorts compared with the ANDIS cohort. In a 2020 study (the largest study conducted in clinics across China) 111 , all subgroups had lower levels of HOMA-β, HOMA-IR and BMI compared with the ANDIS cohort. Severe autoimmune diabetes mellitus occurred at a younger age (mean 42.7 years) than in Swedish people (mean 50.5 years). As with Indian people, severe insulin-deficient diabetes mellitus was more common (24.8% versus 17.5%) than in the ANDIS cohort and occurred >5 years earlier in life. Severe insulin-resistant and moderate obesity-related diabetes mellitus were diagnosed at least a decade earlier in life than in ANDIS. Finally, the mild age-related diabetes mellitus subgroup was less frequent and was diagnosed a decade earlier compared with ANDIS. In the China National Diabetes and Metabolic Disorders Study (CNDMDS), people with newly diagnosed diabetes mellitus were identified in a nationally representative survey, but autoantibodies were unavailable and surrogate measures were used for HbA 1c and C-peptide 114 . The findings were broadly similar to those of the 2020 study 111 , except for lower proportions of severe insulin-deficient diabetes mellitus and severe insulin-resistant diabetes mellitus, higher proportions of moderate obesity-related diabetes mellitus and mild age-related diabetes mellitus, and older age at diagnosis of moderate obesity-related diabetes mellitus 114 . A similar study among hospital inpatients in Beijing reported younger age at diagnosis for severe insulin-deficient diabetes mellitus, but disease durations were unreported 113 . In Hunan, a clinic-based study of people with long disease duration was unable to replicate the ANDIS subgroups 112 .

In comparison with the Chinese cohorts, it appears that Indian people have generally higher levels of insulin resistance across subgroups, along with higher levels of insulin secretion across most subgroups [110] [111] [112] 114 . Severe insulin-deficient diabetes mellitus presented earlier in life (around age 40 years), at a similar BMI, but with higher HOMA-β and HOMA-IR in the Indian cohort than in the Chinese cohorts [110] [111] [112] 114 . Severe insulin-resistant diabetes mellitus also presented earlier in life, but with much lower HOMA-β in the context of higher HOMA-IR in Indian people compared with Chinese people [110] [111] [112] 114 . Moderate obesity-related diabetes mellitus occurred with a similar frequency but with higher BMI, HOMA-β and HOMA-IR values among Indian cohorts compared with Chinese cohorts [110] [111] [112] 114 . Mild age-related diabetes mellitus featured much higher HOMA-β and HOMA-IR among Indian people, but was otherwise generally similar to that seen in Chinese people [110] [111] [112] 114 .

These Indian and Chinese cohorts generally featured younger ages at diagnosis compared with the ANDIS cohort 108, [110] [111] [112] 114 . Although these findings seem to conflict with previous multi-ethnic studies in high-income countries that report a higher incidence of young-onset T2DM among people of Indian origin relative to people of European or Chinese origin 23, 24 , immigrant populations are heterogeneous and vary from the populations from which they emigrated according to socioeconomic status and other factors 25 . Moreover, young-onset T2DM incidence in Canada among men who have emigrated from China has risen over the past decade to surpass that seen in people who are not Chinese Canadian as of 2017 (reF. 25 ). Although selection bias could have inflated the proportion of younger individuals in the clinic-based or hospital-based Chinese studies, new cases of diabetes mellitus in the nationally representative CNDMDS cohort were similarly diagnosed at younger ages compared with the ANDIS cohort 111, 112 . Further research is required to confirm whether these data reflect a skewed distribution towards earlier age at T2DM diagnosis in Chinese people.

One US multi-ethnic cluster-based study included people aged ≥45 years in the MASALA and MESA cohorts examined on average 5.7 years after diagnosis with diabetes mellitus (standard deviation (s.d.) 7.8 years), without data on GAD antibodies 115 . People taking insulin were excluded from the cluster analysis and manually classified on the basis of age at diagnosis. Although the results were not directly comparable to those of ANDIS, five unique subgroups were identified: older age at onset (43%), severe hyperglycaemia (26%), severe obesity (20%), younger age at onset (1%) and requiring insulin medication use (9%). People of Chinese origin were more likely to be classified in the older age at onset subgroup than people of other ethnicities, and less likely to be classified in the severe obesity subgroups, while people of south Asian origin were most likely to be classified in the severe hyperglycaemia subgroup. Although the authors suggested that different metabolic processes might be occurring among south Asian and Chinese populations, further multi-ethnic studies are required to explore this possibility.

Phenotypes of T2DM have also been classified by age at diagnosis 10, 116 . Young-onset T2DM is especially important in Indian and Chinese populations because of their tendency to be diagnosed at an early age (<40 years) [110] [111] [112] 114 , as well as the aggressive course and poor outcomes of this condition 10 .

Rapid β-cell dysfunction. In the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study of 699 mostly Black, white and Hispanic youth with young-onset T2DM (mean age 13.8-14.1 years) randomized to receive metformin with or without rosiglitazone or basal insulin, the oral disposition index declined by 20-35% per year, which is a much faster decline in insulin secretion than that seen in older populations 117 reported that HOMA-β declined by approximately 7% per year in people with newly diagnosed T2DM 118, 119 . In A Diabetes Outcome Progression Trial (ADOPT), HOMA-β declined by approximately 7-11% per year in mostly white, Black and Hispanic adults with T2DM (mean age 56.3-57.9 years) randomized to receive rosiglitazone, metformin or glyburide monotherapy 120 . The percentage decline in HOMA-β was equivalent to a glycaemic deterioration rate of around 0.07-0.14% per year 120 , which is similar in magnitude to that of a Scottish observational cohort 121 .

In China, multiple lines of evidence have confirmed the accelerated rates of β-cell decline in young-onset T2DM. In a Hong Kong population-based study of adults aged 18-75 years, the steepest rates of glycaemic deterioration were among those with young-onset T2DM, especially those diagnosed at age 20 years 122 . Aggressive glycaemic deterioration in young-onset T2DM contributed to persistently increased HbA 1c levels and more than triple the cumulative exposure to hyperglycaemia from diagnosis until age 75 years, compared with usual-onset T2DM (defined here as age at diagnosis ≥40 years) 122 . A national Chinese cross-sectional survey of people with newly diagnosed T2DM showed that HOMA-β was similar across ages at diagnosis, but the difference in HOMA-β between people with T2DM and age-matched control individuals was much greater among people with young-onset than in people with usual-onset T2DM 123 . Furthermore, people with young-onset T2DM had the most abnormal HOMA-IR and oral disposition index out of all the groups in the study 123 . Similarly, a study conducted in India of 82 people aged <25 years with either young-onset T2DM, pre-diabetes or normoglycaemia showed that T2DM was associated with a lower oral disposition index, but not insulin resistance, after adjustment for age and obesity 124 .

Collaboration estimated that people with usual-onset T2DM might die up to 6 years earlier than those without T2DM 125 , but an analysis of the Swedish National Diabetes Registry estimated that those diagnosed with young-onset T2DM at age 15 years might lose 12 years of life compared with people without T2DM 126 . This increased risk of mortality is driven by an elevated risk of T2DM complications compared with usual-onset T2DM [127] [128] [129] [130] .

In China, a national cross-sectional study of 200,000 people with T2DM who were identified using the China National HbA 1c Surveillance System reported that those with young-onset T2DM had an increased prevalence of cardiovascular disease (OR 1.91, 95% CI 1.81-2.02) 131 . In a subset of this population, the prevalence of diabetic kidney disease was also higher among people with young-onset T2DM (5.1%) than those with usual-onset T2DM (1.5%; OR 1.69, 95% CI 1.46-1.95) 132 . In Hong Kong, young-onset T2DM was associated with an increased risk of cardiovascular disease (HR 1.48, 95% CI 1.17-1.88) and diabetic kidney disease (HR 1.35, 95% CI 1.12-1.62) versus usual-onset T2DM 133 . Furthermore, young-onset T2DM was associated with an increased risk of hospitalization owing to mental illness, with 36.1% of all hospitalizations of people with young-onset T2DM before age 40 years attributable to psychiatric conditions, including psychotic disorders and mood disorders 134 . In these studies, the increased risk of complications associated with a younger age at diagnosis was not entirely explained by longer disease duration [131] [132] [133] [134] . The prevalence of complications in China varies along a north to south gradient, with higher rates among northern Chinese populations than southern Chinese populations for both young-onset and usual-onset T2DM 135 .

In India, the epidemiology of complications in young-onset T2DM is described at the local and regional level. In a large diabetes mellitus centre in Chennai, 267 people with young-onset T2DM diagnosed before age 25 years had a similar odds ratio of having diabetic nephropathy (OR 1.07, 95% CI 0.66-1.73) and higher odds ratio of having diabetic retinopathy (OR 2.02, 95% CI 1.38-2.95) compared with 267 people with usual-onset T2DM diagnosed after age 50 years, and metabolic risk factors were more poorly controlled in the young-onset T2DM group 136 . In the same centre, a study of people diagnosed with diabetes mellitus at age 10-25 years found that people with young-onset T2DM had double the odds ratio of having any microvascular or macrovascular complication (OR 2.11, 95% CI 1.27-3.51) compared with people who had T1DM 137 . A subsequent study estimated that the incidence of diabetic nephropathy was 13.8 per 1,000 person-years in T2DM compared with 6.2 per 1,000 person-years in T1DM (attained age <20 years) 138 .

Few international studies have systematically compared complication rates specifically among people with young-onset T2DM in India and China. In a crosssectional study of people with T2DM from out patient clinics across Asia (n = 5,646 (China, public clinics), 15,341 (Hong Kong, public clinics), 9,107 (India, private clinics)), the Joint Asia Diabetes Evaluation programme found that Indian people with young-onset T2DM had a higher prevalence of ischaemic heart disease (India, 8.3%; China, 2.8%; Hong Kong, 5.8%) and diabetic kidney disease (India, 19.7%; China, 1.3%; Hong Kong, 5.7%) than Chinese people; however, differences in disease duration (median: 9.0 years (India), 4.0 years (China) and 14.0 years (Hong Kong)) might have had a role 139 . The prevalence of stroke was higher among Chinese people than in Indian people with young-onset T2DM (China, 1.5%; Hong Kong, 3.3%; India, 0.7%) 139 .

Clinical recommendations for management of young-onset T2DM lack evidence because most intervention studies have been conducted in people with usual-onset T2DM 140, 141 . In China, short-term intensive insulin therapy is a standard treatment option for newly diagnosed T2DM 142 . Younger age at diagnosis predicted a reduced rate of glycaemic relapse (HR 0.75, 95% CI 0.58-0.95 for every 10 years) after 2 weeks of continuous subcutaneous insulin infusion among 124 Chinese adults with newly diagnosed T2DM (mean age 47.33 ± 9.45 years) 143 . A retro spective analysis of a randomized controlled trial that compared subcutaneous insulin infusion therapy

An epidemiological measure of the speed of progression of diabetes mellitus, calculated as the slope of HbA 1c over time after statistical adjustment for glucose-lowering drugs (this rate cannot be determined for people treated with insulin).

The recurrence of type 2 diabetes mellitus (T2DM) in an individual who previously had T2DM in remission.

www.nature.com/nrendo with or without metformin among people with newly diagnosed T2DM showed that people with young-onset T2DM treated with metformin required lower doses of insulin than people with usual-onset T2DM. This finding suggests that people with young-onset T2DM might be more sensitive to metformin than people with usualonset T2DM 144 . By contrast, an observational study of adults in Hong Kong showed that metformin alone or in combination with other drugs was associated with a similar degree of glycaemic lowering among people with young-onset T2DM and usual-onset T2DM 122 . In the TODAY study, metformin monotherapy was associated with treatment failure in 51.7% of people with youngonset T2DM diagnosed at age 10-17 years, with lower treatment failure rates when metformin was combined with rosiglitazone (38.6%) or behavioural intervention (46.6%) 145 . In the Restoring Insulin Secretion study, treatment for 3 months with insulin glargine followed by 9 months with metformin improved β-cell function compared with metformin monotherapy among adults diagnosed with T2DM at ages 20-65 years, but not among those diagnosed at ages 10-19 years 146 .

Additionally, early combination therapy with multiple glucose-lowering agents 147 is a promising strategy for young-onset T2DM. In a 5-year randomized clinical trial, early treatment with metformin and the dipeptidyl peptidase 4 (DPP4) inhibitor vildagliptin led to greater and more durable glycaemic lowering compared with a sequential strategy of metformin followed by augmentation with vildagliptin 148, 149 . These effects were similar in Asian people and people who are not Asian 148 , and the benefit was even greater in young-onset T2DM than usual-onset T2DM (48% versus 24% reduction in risk of treatment failure) 150 .

Reducing the incidence of microvascular and macrovascular complications requires optimal glycaemic control, a fundamental cornerstone of multifactorial T2DM management 151 . Multiple classes of non-insulin pharmacological agent are commonly used to treat hyperglycaemia. In accordance with their distinctive pathophysiology and phenotypes, Indian and Chinese people with T2DM respond differently to many of these medications compared with other populations (TABle 2) .

The efficacy of metformin as a treatment for T2DM was first demonstrated in the UKPDS study 152 . Subsequent studies have verified that metformin lowers glucose levels efficaciously among Chinese and south Asian people 153 , and improves β-cell function among Indian people 154 and Chinese 155 people without obesity. However, no studies to our knowledge have directly compared its effects across Chinese, Indian and other populations.

In China, the Metformin and Acarbose in Chinese as the Initial Hypoglycaemic Treatment study reported that acarbose was not inferior to metformin in HbA 1c lowering (mean difference 0.01%, 95% CI −0.12% to 0.14%), and resulted in better weight reduction and improved levels of lipids compared with metformin 156 . A meta-analysis comparing acarbose with DPP4 inhibitors also reported that acarbose had superior weight loss efficacy with a similar degree of glucose lowering 157 . In western populations with IGT, acarbose was found to reduce the risk of developing T2DM (HR 0.75, 95% CI 0.63-0.90) compared with placebo 158 . A meta-analysis of randomized controlled trials reported that acarbose had a greater HbA 1c -lowering effect among east Asian populations than in western populations (1.26% (s.d. 1.20%) versus 0.62% (s.d. 1.28%)) 159 . This difference was postulated to be driven by the fairly large proportion of starch content in east Asian diets 160 . An observational study of 21 countries also found that east and southeast (defined here as having an ethnic origin from Indonesia, Philippines, Thailand, Vietnam, Malaysia, Cambodia or Singapore) Asian people had larger HbA 1c reductions with acarbose compared with south Asian people and European people 161 . These findings conflict with other systematic reviews reporting similar HbA 1c -lowering effects in east Asian people and western people 162, 163 . The incidence of diarrhoea as an adverse effect might be less common in Asian people than people who are not Asian 163 . This finding may be most applicable to east Asian people because the Asian populations included within this meta-analysis were predominantly east Asian. In a trial among Chinese people with coronary artery disease and IGT, acarbose prevented the onset of diabetes mellitus but did not reduce the frequency of cardiovascular events 164 .

Although sulfonylureas can cause hypoglycaemia and weight gain 165 , they are cheap and are the second most common oral glucose-lowering medication in India [166] [167] [168] and China 169,170 after metformin. Glycaemic improvements with sulfonylureas might be less durable compared with improvements with other classes of glucose-lowering medication owing to accelerated β-cell failure, especially with older sulfonylureas 165 . In ADOPT, the incidence of elevated fasting blood levels of glucose >10.0 mmol/l after a median of 4.0 years of treatment was 34% for glyburide compared with 21% and 15% for metformin and rosiglitazone, respectively 120 . A cluster-based analysis of the ADOPT cohort showed that glycaemic deterioration was the steepest among those with severe insulin-deficient diabetes mellitus treated with glyburide, while those with mild age-related diabetes mellitus showed the greatest benefit 116 . An intensive glucose-lowering strategy using modified-release gliclazide, a modern sulfonylurea, successfully lowered HbA 1c to 6.5% after a median of 5 years in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial 171 . A sub-analysis of the ADVANCE trial showed that HbA 1c lowering was similar among Asian people (defined in this study as people from China, India, Malaysia and the Philippines) (−0.78%, 95% CI −0.83% to −0.74%) and eastern European people (−0.71%, 95% CI −0.78% to −0.64%) 172 . Secondary analyses of clinical trials suggest that sulfonylureas lower blood levels of glucose more effectively among men of 

Activates AMPactivated protein kinase, reduces hepatic glucose production, enhances insulin-mediated glucose uptake, increases glucose utilization and GLP1 secretion in the gut without weight gain or hypoglycaemia [219] [220] [221] Probably efficacious in Asian people 153 

Nature reviews | Endocrinology

European origin without obesity, and less effectively among women of European origin with obesity, compared with thiazolidinediones 173, 174 . These findings have not been replicated in Indian and Chinese populations.

DPP4 inhibitors lower blood levels of glucose by restoring first-phase insulin secretion in a glucose-dependent manner and suppressing abnormally elevated glucagon levels 175, 176 , thus targeting two crucial issues in T2DM and IGT 177 . These features of DPP4 inhibitors are especially important in the context of β-cell dysfunction among Indian and Chinese people. Although the initial uptake of DPP4 inhibitors was slow in China 170, 178 and India 168 , their popularity seems to be rapidly increasing [178] [179] [180] , especially with the availability of low-cost tenegliptin in India 181 . In the Trial Evaluating Cardiovascular Outcomes with Sitagliptin study, east Asian people had the greatest initial reduction in HbA 1c (−0.60%) compared with other groups (≤0.55% reduction) 182 . This greater effect in east Asian people has been attributed to the restoration of first-phase insulin secretion 176 . Lower levels of insulin resistance among east Asian people 111, 112, 114 relative to people of European origin 108 could also have a role, as insulin resistance is associated with less-effective glucose lowering with DPP4 inhibitors among people of European origin 183 . Further research is required to confirm whether these findings extend to Indian people 184 . A meta-analysis that compared randomized controlled trials including mostly Asian participants with trials that included mostly participants who were not Asian found that DPP4 inhibitors lowered HbA 1c better in Asian people than in people who were not Asian (between-group HbA 1c difference -0.26%, 95% CI -0.36% to -0.17%) 185 . Another meta-analysis that compared randomized controlled trials that included mostly white participants with trials that included mostly Asian participants reported similar HbA 1c lowering in white people (−0.49%, 95% CI −0.59% to −0.38%) and Asian people (−0.62%, 95% CI −0.8% to −0.45%) 186 , but a sensitivity analysis restricted to studies 12-52 weeks in duration showed greater HbA 1c lowering among Asian people (mostly east Asian people; −0.73%, 95% CI −0.88% to −0.57%) versus white people (−0.49%, 95% CI −0.59% to −0.39%) 186 . An additional meta-analysis reported better glucose lowering with DPP4 inhibitors in Asian people compared with white people (between-group HbA 1c difference -0.18%, 95% CI -0.32% to -0.04%), but improvements in HOMA-β were smaller in Asian people than in white people 187 . Similar findings have been described with DPP4 inhibitor and metformin combination therapy 188 .

A meta-analysis reported that pioglitazone and rosiglitazone are efficacious in lowering HbA 1c among Chinese, Indian and other Asian people 189 , but, to our knowledge, there are no studies comparing Chinese, Indian or Asian people in general with people who are not Asian. In a UK study of 177 people of Indian descent with T2DM, rosiglitazone reduced HbA 1c by 1.16% compared with placebo and improved insulin sensitivity and β-cell function 190 . Similar findings have been described with pioglitazone in China 191 . In the multi-ethnic Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication trial, rosiglitazone was less efficacious in reducing the incidence of diabetes mellitus in south Asian people than in people of other ethnicities 192 . An international observational study reported that pioglitazone and rosiglitazone are associated with increased hospitalization for heart failure in Australia and Canada, but not in east Asian countries or regions 193 . In European populations, pioglitazone reduces all-cause mortality, myocardial infarction and stroke among people with T2DM 194, 195 , especially those with insulin resistance 196 study suggested that pioglitazone was associated with a 30% reduction in myocardial infarction, heart failure and stroke 197 . Pioglitazone is commonly used in China (5.6-17.0% of people with T2DM who are treated with oral agents) 169, 170 and India (regularly prescribed by 56.2% of Indian physicians) 198, 199 .

Several meta-analyses of randomized controlled trials have shown that SGLT2 inhibitors are probably similarly 200, 201 or more 186 effective in reducing blood levels of glucose and body weight, and similarly effective in reducing the incidence of adverse cardiovascular events 202 , in Asian people and people who were not Asian or white people. It is unknown whether these effects might differ between Indian people and Chinese people 186, 200 . Although SGLT2 inhibitors are widely recom mended among Asian populations [203] [204] [205] , data on the real-world use of SGLT2 inhibitors in China and India are scarce. In Hong Kong, the use of SGLT2 inhibitors increased rapidly from 2015 to 2016 (0.04% to 0.4% of non-insulin glucose-lowering medications) 178 .

In India, the availability of low-cost remogliflozin and future generic options will probably expand the uptake of this class 168, 206 .

In a secondary analysis of a randomized controlled trial, the glucagon-like peptide 1 (GLP1) receptor agonist liraglutide lowered blood levels of glucose by a similar degree among south Asian people and western European people 207 . A meta-analysis comparing 19 studies including predominantly white participants with three studies including predominantly Asian participants found that the glucose-lowering efficacy of GLP1 receptor agonists was similar across both groups 186 . A similar meta-analysis reported that the glucose-lowering effectiveness seemed to be similar among Asian people and people who are not Asian regardless of baseline weight 208 . Previous meta-analyses comparing cardiovascular risk reduction among Asian people and people who are not Asian reported mixed findings 209, 210 , but an updated meta-analysis of six cardiovascular outcome trials for GLP1 receptor agonists reported that reductions in major adverse cardiovascular events were greater among Asian people than in white people 202 . Emerging evidence suggests that GLP1 receptor agonists could be more effective when initiated early in the course of disease among people with adequate β-cell function 211 . In the prospective observational Predicting Response to Incretin Based Agents study, long duration of diabetes mellitus, low C-peptide concentrations, treatment with insulin and positive GAD or islet antibodies were associated with reduced lowering of blood levels of glucose 211 . However, a post hoc analysis of A Study in Participants With Type 2 Diabetes Mellitus found that dulaglutide lowered blood levels of glucose similarly among people with high and low titres of GAD antibodies 212 . In China, a retrospective cohort study reported that those with a shorter duration of T2DM and a higher baseline HbA 1c had greater reductions in levels of glucose with exenatide 213 , a finding that has been replicated in Korean people 214 . Similar studies have not been conducted among Indian people. GLP1 receptor agonists are not commonly used in India 168 or China 170, 178 owing to barriers such as high costs 215 .

Although the massively growing burden of T2DM in India and China has been strongly driven by rapid urbanization, these populations also have an inherent, shared predisposition to deficient insulin secretion. This susceptibility confers an increased risk of severe insulin-deficient diabetes mellitus occurring even among lean people at young ages <40 years. Other subtypes of T2DM also seem to present earlier in life and with lower β-cell function, lower insulin resistance and lower BMI among Chinese people and most Indian people compared with European people. These distinctions are key to deciphering the unique responses to glucose-lowering medications among Indian and Chinese populations. In particular, incretin-based therapies have a key role in enhancing pancreatic β-cell function in these populations, providing effective glucose lowering with DPP4 inhibitors and providing highly effective glucose lowering with GLP1 receptor agonists if initiated early in the course of disease when β-cell function is still fairly well preserved. Informed by these differences, future precision medicine strategies should be adapted, recalibrated and rigorously validated among Indian and Chinese populations. In particular, better treatments tailored to phenotype are required for those diagnosed at the youngest ages, and further work is required to identify effective early combination therapies. Future research will need to integrate basic sciences, clinical, epidemiological, genetic and other sources of data 216 to better characterize and treat the unique pathophysiology and phenotypes of T2DM in India and China, and throughout their global diasporas.

Published online xx xx xxxx

Harnessing heterogeneity in type 2 diabetes mellitus

Heterogeneity of diabetes: heralding the era of precision medicine

Precision medicine in the management of type 2 diabetes

Precision medicine in type 2 diabetes

Precision medicine in diabetes: a consensus report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

IDF. IDF Diabetes Atlas, 10th Edition Committee. IDF Diabetes Atlas (International Diabetes Federation

An authoritative source of country-specific estimates of the prevalence of diabetes mellitus

Diabetes among non-overweight individuals: an emerging public health challenge

Cardiometabolic abnormalities among normal-weight persons from five racial/ethnic groups in the United States: a cross-sectional analysis of two cohort studies

Diabetes in normalweight individuals: high susceptibility in nonwhite populations

Young-onset type 2 diabetes mellitus -implications for morbidity and mortality

An informative Review of the epidemiology, risk factors, pathogenesis and outcomes of young-onset T2DM

Secular trends in incidence of type 1 and type 2 diabetes in Hong Kong: a retrospective cohort study

Prevalence and trends of the diabetes epidemic in South Asia: a systematic review and meta-analysis

Diabetes mellitus and its complications in India

Atypical forms of diabetes mellitus in Africans and other non-European ethnic populations in low-and middle-income countries: a systematic literature review

Incidence of diabetes and pre-diabetes in a selected urban south Indian population

Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10-year follow-up of the Chennai Urban Rural Epidemiology Study (CURES)

1597-P: Incidence of diabetes in young adult south Asians compared with Pima Indians

Lifetime risk of diabetes in metropolitan cities in India

a population-based study of the incidence and risk factors

Incidence of type 2 diabetes mellitus and prediabetes in Kerala, India: results from a 10-year prospective cohort

Incidence and time trends of type 2 diabetes mellitus among adults in Zhejiang Province, China

Comparison of the incidence of diabetes in United States and Indian youth: an international harmonization of youth diabetes registries

Ethnicity and sex affect diabetes incidence and outcomes

Diabetes in the young: a population-based study of South Asian, Chinese and White people

Migration and diabetes incidence among Chinese adults in Canada, China, Hong Kong, and Taiwan: an international population-based comparative study from

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes?

Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function

Cell secretory dysfunction: a key cause of type 2 diabetes

Age trajectories of glycaemic traits in non-diabetic South Asian and white individuals: the Whitehall II cohort study

A classic prospective British study that compares serially measured glucose levels, insulin sensitivity and insulin secretion among south Asian and white individuals without diabetes mellitus followed over a 20-year period

Failing beta-cell adaptation in South Asian families with a high risk of type 2 diabetes

Understanding the high prevalence of diabetes in U.S. South Asians compared with four racial/ethnic groups: The MASALA and MESA studies

An important study conducted in the USA comparing diabetes mellitus prevalence, insulin secretion and insulin resistance across ethnicities

Ethnic differences in the relationship between insulin sensitivity and insulin response

Incidence of diabetes in South Asian young adults compared to Pima Indians

An interesting comparison of T2DM incidence, BMI, insulin secretion and insulin resistance in south Asian people living in India and Pakistan compared with the Pima Indian people in the USA

Incidence and pathophysiology of diabetes in South Asian adults living in India and Pakistan compared with US blacks and whites

Ethnic differences in insulin sensitivity and beta-cell function among Asian men

The relative associations of β-cell function and insulin sensitivity with glycemic status and incident glycemic progression in migrant Asian Indians in the United States: the MASALA study

Evidence of reduced β-cell function in asian indians with mild dysglycemia

Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation

Metabolic characteristics of subjects with normal glucose tolerance and 1-h hyperglycaemia

Decreased beta cell function and insulin sensitivity contributed to increasing fasting glucose in Chinese

Differential role of insulin resistance and β-cell function in the development of prediabetes and diabetes in middle-aged and elderly Chinese population

Association of insulin resistance and β-cell dysfunction with incident diabetes among adults in China: a nationwide, population-based, prospective cohort study

A national study of the associations of insulin secretion and insulin resistance with the incidence of diabetes mellitus according to BMI levels in China

Prediabetes": are there problems with this label? No, we need heightened awareness of this condition! Diabetes Care

Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose

An informative discussion of the distinct metabolic features of impaired fasting glucose and impaired glucose tolerance

Insulin resistance versus β-cell dysfunction in type 2 diabetes: where public and personalised health meet

Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study

Prevalence of prediabetes among adolescents and young adults in the United States

Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance

Why are South Asians prone to type 2 diabetes? A hypothesis based on underexplored pathways

Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men

Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study

A national study of the prevalence of diabetes mellitus in China

Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance does it matter?

High-normal 2 h glucose is associated with defects of insulin secretion and predispose to diabetes in Chinese adults

Insulin resistance, beta-cell function, adipokine profiles and cardiometabolic risk factors among Chinese youth with isolated impaired fasting glucose versus impaired glucose tolerance: the BCAMS study

Impact of impaired fasting glucose and impaired glucose tolerance on arterial stiffness in an older Chinese population: the Guangzhou Biobank Cohort Study-CVD

Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps

Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis

Progress in defining the genetic contribution to type 2 diabetes in individuals of east asian ancestry

An informative discussion about how genetic discovery sheds light on the pathophysiology of T2DM

The trans-ancestral genomic architecture of glycemic traits

Identification of type 2 diabetes loci in 433,540 East Asian individuals

The largest meta-analysis of GWAS of loci associated with T2DM in east Asian populations

Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci

Genome-wide association study for type 2 diabetes in indians identifies a new susceptibility locus at 2q21

Genome-wide association study identifies a novel locus contributing to type 2 diabetes susceptibility in sikhs of Punjabi origin from India

Ethnic differences in adiposity and diabetes risk-insights from genetic studies

Integrating linguistics, social structure, and geography to model genetic diversity within India

Replication of newly identified type 2 diabetes susceptible loci in northwest Indian population

Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians

Change in β-cell mass in Japanese nondiabetic obese individuals

The Pax4 gene is essential for differentiation of insulin-producing β cells in the mammalian pancreas

Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses

Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients

A variant of PSMD6 is associated with the therapeutic efficacy of oral antidiabetic drugs in Chinese type 2 diabetes patients

Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: a cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank

Pharmacogenetics of novel glucose-lowering drugs

Type 2 (non-insulindependent) diabetes mellitus: the thrifty phenotype hypothesis

Poverty and Famines: An Essay on Entitlement and Deprivation

Exposure to the chinese famine in early life and the risk of hyperglycemia and type 2 diabetes in adulthood

Is exposure to famine in childhood and economic development in adulthood associated with diabetes?

Intrauterine programming of obesity and type 2 diabetes

Ten SNPs may affect type 2 diabetes risk in interaction with prenatal exposure to chinese famine

Developmental origins of the metabolic syndrome: prediction, plasticity, and programming

Developmental origins of diabetes -an Indian perspective

Exposing the exposures responsible for type 2 diabetes and obesity

Two decades since the fetal insulin hypothesis: what have we learned from genetics?

Intrauterine exposure to maternal diabetes is associated with higher adiposity and insulin resistance and clustering of cardiovascular risk markers in Indian children

Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes

Islet amyloid polypeptide, islet amyloid, and diabetes mellitus

Prevalence and clinicopathological characteristics of islet amyloid in chinese patients with type 2 diabetes

A comparison of the healthiness of packaged foods and beverages from 12 countries using the Health Star Rating nutrient profiling system

The islet amyloid polypeptide (amylin) gene S20G mutation in Chinese subjects: evidence for associations with type 2 diabetes and cholesterol levels

The islet amyloid polypeptide gene and non-insulin-dependent diabetes mellitus in South Indians

The S20G substitution in hIAPP is more amyloidogenic and cytotoxic than wild-type hIAPP in mouse islets

Role of gut microbiota in type 2 diabetes pathophysiology

Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

Burden of infection and insulin resistance in healthy middle-aged men

Infections: a possible risk factor for type 2 diabetes

A study of seroprevalence of hepatitis B and C in type 2 diabetes patients in a tertiary care teaching institute in South India

Association of hepatitis B surface antigen seropositivity and hepatitis B surface antibody seropositivity with diabetes: a cross-sectional study based on two Chinese populations in Guangdong, China

Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection

The bidirectional relationship between tuberculosis and diabetes

Tuberculosis and diabetes mellitus: convergence of two epidemics

Helicobacter pylori infection is associated with type 2 diabetes among a middle-and old-age Chinese population

Helicobacter pylori infection in Chinese subjects with type 2 diabetes

Novel subgroups of adult-onset diabetes and their association with outcomes: a datadriven cluster analysis of six variables

Novel diabetes subgroups

Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study

This study is the first to investigate the subgroups of diabetes mellitus in India

Validation of the Swedish diabetes re-grouping scheme in adult-onset diabetes in China

Identification of two novel subgroups in patients with diabetes mellitus and their association with clinical outcomes: a two-step cluster analysis

Application of new international classification of adult-onset diabetes in Chinese inpatients with diabetes mellitus

Novel subgroups of patients with adult-onset diabetes in Chinese and US populations

An interesting analysis comparing subgroups of diabetes mellitus across ethnicities in the USA

Association of diabetes subgroups with race/ethnicity, risk factor burden and complications: the MASALA and MESA studies

Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data

An interesting comparison of subgroup-based approaches versus model-based approaches to predicting T2DM outcomes

Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY

Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

A classic trial that demonstrates how T2DM progresses differently among people treated with various glucose-lowering drugs

Rates of glycaemic deterioration in a real-world population with type 2 diabetes

Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: a population-based observational study

The characteristics of newly diagnosed adult early-onset diabetes: a population-based cross-sectional study

Associations of β-cell function and insulin resistance with youth-onset type 2 diabetes and prediabetes among Asian Indians

A classic paper describing the mortality outcomes of diabetes mellitus in 97 prospective cohorts

An observational study that demonstrates how age at diagnosis affects cardiovascular and mortality outcomes of T2DM

Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians

Age, age at diagnosis and diabetes duration are all associated with vascular complications in type 2 diabetes

Short-term progression of cardiometabolic risk factors in relation to age at type 2 diabetes diagnosis: a longitudinal observational study of 100,606 individuals from the Swedish National Diabetes Register

Long-term complications in youth-onset type 2 diabetes

Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study

Prevalence of microvascular diseases among tertiary care Chinese with early versus late onset of type 2 diabetes

Premature mortality and comorbidities in young-onset diabetes: a 7-year prospective analysis

Excess burden of mental illness and hospitalization in young-onset type 2 diabetes

Greater macrovascular and microvascular morbidity from type 2 diabetes in northern compared with southern China: a cross-sectional study

Younger-onset versus olderonset type 2 diabetes: clinical profile and complications

Incidence of complications in young-onset diabetes: comparing type 2 with type 1 (the young diab study)

Clinical profile and incidence of microvascular complications of childhood and adolescent onset type 1 and type 2 diabetes seen at a tertiary diabetes center in India

Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort

Cardiovascular outcomes trials in type 2 diabetes: time to include young adults

Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials

Standards of medical care for type 2 diabetes in China

An article that summarizes the standard approaches to the pharmacological management of T2DM recommended in China

Predictors of long-term glycemic remission after 2-week intensive insulin treatment in newly diagnosed type 2 diabetes

Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients

A clinical trial to maintain glycemic control in youth with type 2 diabetes

Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on β-cell function: comparison of responses in youth and adults

Costarting sitagliptin with metformin is associated with a lower likelihood of disease progression in newly treated people with type 2 diabetes: a cohort study

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes mellitus-an East Asian perspective

Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study

Effect of a multifactorial intervention on mortality in type 2 diabetes

Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes

Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: an Asian-Pacific perspective

Metformin upregulates mitophagy in patients with T2DM: a randomized placebo-controlled study

The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes

Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial

Acarbose with comparable glucose-lowering but superior weightloss efficacy to dipeptidyl peptidase-4 inhibitors: a systematic review and network meta-analysis of randomized controlled trials

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an eastern or western diet: a systematic meta-analysis

An importance of carbohydrate ingestion for the expression of the effect of α-glucosidase inhibitor in NIDDM

Efficacy of acarbose in different geographical regions of the world: analysis of a reallife database

Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian

Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

The place of gliclazide MR in the evolving type 2 diabetes landscape: a comparison with other sulfonylureas and newer oral antihyperglycemic agents

Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: a consensus statement

The position of gliclazide in the evolving landscapes and disease continuum of T2DM: a collaborative delphi survey-based consensus from India

Drug prescription patterns and cost analysis of diabetes therapy in India: audit of an endocrine practice. Indian

China type 2 diabetes treatment status survey of treatment pattern of oral drugs users

Treatment patterns in patients with newly diagnosed type 2 diabetes in china: a retrospective, longitudinal database study

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial

Precision medicine in type 2 diabetes: using individualized prediction models to optimize selection of treatment

Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and individual trial data

Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors

Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance

Trends in glucose-lowering drug use, glycemic control, and severe hypoglycemia in adults with diabetes in Hong Kong

DPP-4 inhibitor treatment in chinese type 2 diabetes patients: a meta-analysis

Penetration of new antidiabetic medications in East Asian countries and the United States: a cross-national comparative study

Indian Expert Review on Use of teneligliptin in patients with diabetes and its safety and efficacy (INTENSE)

Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

Precision medicine in type 2 diabetes: clinical markers of insulin resistance are associated with altered short and long-term glycemic response to DPP4-inhibitor therapy

Incretin response in Asian type 2 diabetes: are Indians different? Indian

A reasonably large meta-analysis of clinical trial data showing distinctive HbA 1c responses to various classes of glucose-lowering drugs among Asian people

Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in white and asian patients with diabetes: a systematic review and metaanalysis of randomized controlled trials

Efficacy of dipeptidylpeptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis

safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis

A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations

Rosiglitazone in type 2 diabetes mellitus: an evaluation in British Indo-Asian patients

Pioglitazone improved insulin sensitivity and first phase insulin secretion among obese and lean people with diabetes: a multicenter clamp study

Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

Variation in association between thiazolidinediones and heart failure across ethnic groups: retrospective analysis of large healthcare claims databases in six countries

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

Cardiovascular effects of pioglitazone or sulfonylureas according to pretreatment risk: moving toward personalized care

Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes

Pioglitazone: Indian perspective. Indian

Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: a multicentre questionnaire-based observational study. Indian

No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: a meta-analysis

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in East Asians with type 2 diabetes: a systematic review and meta-analysis

A reasonably large meta-analysis showing how Asian people might experience greater benefits of reduced cardiovascular and heart failure events with treatment using SGLT2 inhibitors and GLP1 receptor agonists compared with people who are not Asian

Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2is and GLP-1RAs in Asian versus white patients with and without type 2 diabetes

Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: an Asian perspective and expert recommendations

Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: an Asian perspective and expert recommendations

Pharmacological management of South Asians with type 2 diabetes: consensus www.nature.com/nrendo 0123456789();: recommendations from the South Asian Health Foundation

Remogliflozin etabonate in the treatment of type 2 diabetes: design, development, and place in therapy

Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies

Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/ obesity: meta-analysis of randomized controlled trials

Subpopulation differences in the cardiovascular efficacy of long-acting glucagon-like peptide 1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-analysis

Asian subpopulations may exhibit greater cardiovascular benefit from long-acting glucagon-like peptide 1 receptor agonists: a metaanalysis of cardiovascular outcome trials

Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes

Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4 and -5 trials

Predictive factors associated with glycaemic response to exenatide in Chinese patients with type 2 diabetes mellitus

Clinical efficacy and parameters affecting the response to dulaglutide treatment in patients with type 2 diabetes: a retrospective, realworld data study

Consensus recommendations on GLP-1 RA use in the management of type 2 diabetes mellitus: south asian task force

A highly comprehensive summary of the current gaps in the prevention and management of diabetes mellitus

Indian Council of Medical Research. ICMR Guideline for Management of Type 2 Diabetes

A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

The target of metformin in type 2 diabetes

The mechanisms of action of metformin

Cellular and molecular mechanisms of metformin action

Chinese expert consensus statement on metformin in clinical practice

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial

Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial

Cardiovascular effects of new oral glucose-lowering agents

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Glucose-lowering drugs and hospitalization for heart failure: a systematic review and additive-effects network meta-analysis with more than 500 000 patient-years

Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-theart review

Evidence-based consensus on positioning of SGLT2i in type 2 diabetes mellitus in Indians

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes

Canagliflozin and cardiovascular and renal events in type 2 diabetes

Dapagliflozin and cardiovascular outcomes in type 2 diabetes

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network metaanalysis of randomised controlled trials

Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications

Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71,553 individuals

Expert consensus on glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. Chin

The cardiovascular biology of glucagon-like peptide-1

Liraglutide and cardiovascular outcomes in type 2 diabetes

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a doubleblind, randomised placebo-controlled trial

Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

Lixisenatide in patients with type 2 diabetes and acute coronary syndrome

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

Chinese Society of Endocrinology & Chinese Diabetes Society. [Consensus recommendations on utilizing glucagon-like pepetide-1 (GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus

Suite of food security indicators

Food and Agriculture Organization of the United Nations. The Future of Food and Agriculture-Alternative Pathways to 2050

Mysteries of type 2 diabetes: the Indian elephant meets the Chinese dragon

Causes of type 2 diabetes in China

An insightful review of the causes of T2DM in China

Epidemiology and determinants of type 2 diabetes in south Asia

An insightful review of the epidemiology of T2DM in south Asia

White rice intake and incident diabetes: a study of 132,373 participants in 21 countries

Predicting population age structures of China, India, and Vietnam by 2030 based on compositional data

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants

United Nations, Department of Economic and Social Affairs, & Population Division

The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease study 1990-2016

Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia study

Finding the missing heritability of complex diseases

Type 2 diabetes: genetic data sharing to advance complex disease research

Changes in adult smoking behaviours in ten global adult tobacco survey (GATS) countries during 2008-2018 -a test of 'hardening' hypothesis

Trends in bidi and cigarette smoking in India from 1998 to 2015, by age, gender and education

Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis

Global effects of smoking, of quitting, and of taxing tobacco

Geographical variation in diabetes prevalence and detection in china: multilevel spatial analysis of 98,058 adults

Sex differences in the association between socioeconomic status and diabetes prevalence and incidence in China: cross-sectional and prospective studies of 0.5 million adults

Diabetes prevalence and its relationship with education, wealth, and BMI in twenty-nine low-and middle-income countries

World Health Organization. Global Spending on Health: Weathering the Storm (World Health Organization

The health care systems of China and India: performance and future challenges

Catastrophic health expenditure on acute coronary events in Asia: a prospective study

Diabetes in China: a societal solution for a personal challenge

Public health and health systems: implications for the prevention and management of type 2 diabetes in south Asia

Cross-cultural variation in symptom perception of hypoglycemia

Factors influencing diabetes self-management in Chinese people with type 2 diabetes

International Diabetes Federation and the DAR International Alliance. Diabetes and Ramadan: Practical Guidelines 2021 (International Diabetes Federation

Pragmatic dietary advice for diabetes during Navratris

Litchi chinensis: medicinal uses, phytochemistry, and pharmacology

A unique understanding of traditional medicine of pomegranate, Punica granatum L. and its current research status

Nutrient components, health benefits, and safety of litchi (Litchi chinensis Sonn.): a review

Litchi-related hypoglycemia: a public health challenge, an endocrine opportunity

Role of gut microbiota on onset and progression of microvascular complications of type 2 diabetes (T2DM)

Glucose clamp technique: a method for quantifying insulin secretion and resistance

Use and abuse of HOMA modeling

Assessment of pancreatic β-cell function: review of methods and clinical applications

Review of methods for measuring β-cell function: design considerations from the Restoring Insulin Secretion (RISE) Consortium

Coefficient of failure: a methodology for examining longitudinal β-cell function in type 2 diabetes

The burden of treatment failure in type 2 diabetes

 Table 1 .

C.K. researched data for the article, wrote the article, contributed substantially to the discussion of content and reviewed and/or edited the manuscript before submission. K.M.V.N, J.C.N.C., P.J. and B.R.S. contributed substantially to the discussion of content and reviewed and/or edited the manuscript before submission.

C.K. reports consulting fees and honoraria from Sanofi, Abbott, and AstraZeneca. The other authors declare no competing interests.

Nature Reviews Endocrinology thanks Sanjay Kalra, who co-reviewed with Madhur Verma, and Yingli Lu for their contribution to the peer review of this work.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.